Biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Tuesday an expanded collaboration and licence agreement with biotech company Exelixis Inc (NASDAQ:EXEL) to develop Cabometyx (cabozantinib) for pancreatic and extra-pancreatic neuroendocrine tumors (pNETs and epNETs) outside the US and Japan.
The deal follows positive results from the CABINET Phase III trial, which showed that Cabometyx improved progression-free survival compared to placebo in patients with advanced pNETs and epNETs.
Ipsen plans to seek marketing authorisation for Cabometyx in this indication in the European Union.
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
NKGen Biotech receives US FDA Fast Track designation for troculeucel in Alzheimer's treatment
Neuphoria Therapeutics to receive USD15m milestone payment from Merck
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Royalty Pharma to invest up to USD250m in Biogen's lupus treatment
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
IXICO's AI platform validated in Huntington's Disease research
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Spinogenix reveals topline results from Phase 2 study in Fragile X syndrome
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval